Up 298% in a Year, Is Hims & Hers Health Still a Buy?
The healthcare company is on fire, and it's still cheap by many measures.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Undeservedly Undervalued
H&H's strong Q3 results signals a fundamental shift in the healthcare industry. GLP-1 drugs are certainly a growth catalyst for H&H but it is just a tiny component of the overall investment thesis. H&H investments in AI will drive massive efficiency gains while delivering immense value for providers and patients.
Hims & Hers: A High-Growth Gem On The Verge Of Big Upside
Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported a 77% year-over-year revenue growth, with a subscriber base of 2 million. Hims & Hers' strategic marketing investments have led to positive net income, with potential for further growth and profitability.
Earnings Estimates Moving Higher for Hims & Hers Health (HIMS): Time to Buy?
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
After Another Blowout Quarter of Surging Revenue, Is Hims & Hers Stock a Once-in-a-Decade Buy?
Hims & Hers strong performance involves much more than just GLP-1 drugs.
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
The company expects to enjoy many GLP-1 tailwinds in 2025.
Hims & Hers: Why This Healthcare Stock's Growth Makes It a Buy
Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thinking that it is now too late to get into action. This might be the case for shares of Hims & Hers Health Inc. NYSE: HIMS, as the stock is now rallying by over 6% the morning after the company reported its quarterly earnings.
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health (HIMS) reported third-quarter results that topped analysts' expectations Monday, lifting its shares, as the company said t plans to release a generic version of a Novo Nordisk (NVO) diabetes and weight-loss drug as early as next year.
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health, Inc. reported record Q3 '24 revenues of over $400 million, beating estimates by nearly $19 million, and guided for up to 90% growth in Q4. The online health and wellness platform saw a 44% YoY subscriber growth, reaching 2 million subscribers, led by 175% growth in personalized services. Despite booming sales and strong financials, the stock remains undervalued, trading below 3x 2025 sales targets and only 22x updated adjusted EBITDA.
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.
